Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act 1934

Date of Report (Date of earliest event reported): December 3, 2007

Titan Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-13341   94-3171940
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

400 Oyster Point Blvd., Suite 505,
South San Francisco, CA
  94080
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: 650-244-4990

  


(Former Name or Former Address, is Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



Item 8.01. Other Events.

On December 3, 2007, Titan Pharmaceuticals, Inc. issued a press release announcing the early completion of enrollment in its Phase III clinical study of Probuphine in the treatment of opioid dependence. A copy of the press release is attached hereto as Exhibit 99.1

 

Item 9.01. Financial Statements and Exhibits.

 

Exhibit No.   

Description

99.1    Press Release issued December 3, 2007.

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

TITAN PHARMACEUTICALS, INC.
By:   /s/ Robert E. Farrell
  Name: Robert E. Farrell
  Title:   Chief Financial Officer

Dated: December 3, 2007

 

3


Exhibit Index

 

Exhibit No.   

Description

99.1    Press Release issued December 3, 2007.

 

4